BMY - Bristol-Myers Squibb Company
49.73 -0.01 (-0.02%)
After hours: 4:57PM EDT
| Previous Close | 49.47 |
| Open | 49.49 |
| Bid | 49.17 x 1000 |
| Ask | 50.08 x 900 |
| Day's Range | 49.35 - 50.10 |
| 52 Week Range | 42.48 - 63.69 |
| Volume | 9,655,032 |
| Avg. Volume | 12,705,779 |
| Market Cap | 81.363B |
| Beta (3Y Monthly) | 0.59 |
| PE Ratio (TTM) | 13.10 |
| EPS (TTM) | 3.80 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 1.64 (3.32%) |
| Ex-Dividend Date | 2019-07-03 |
| 1y Target Est | 58.13 |
- Zacks
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
Bristol-Myers Squibb (BMY) closed at $49.74 in the latest trading session, marking a +0.55% move from the prior day.
- Zacks
Novartis Announces New Data on Spondylitis Drug Cosentyx
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
- Zacks
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
- Zacks
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- Zacks
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
- GuruFocus.com
Seth Klarman's Favorite Health Care Stocks
Klarman has the beaten-up sector as the second-largest in his portfolio Continue reading...
- GuruFocus.com
Gilead Tops List of Most Innovative Drug Companies
Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...
- GuruFocus.com
2 Large-Cap Companies Declare Dividends
Bristol-Myers Squibb, Colgate-Palmolive have appealing yields Continue reading...
- Zacks
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
- Zacks
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
- Zacks
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
- Zacks
Top Ranked Income Stocks to Buy for September 12th
Top Ranked Income Stocks to Buy for September 12th
- Zacks
Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
- Business Wire
Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019
Bristol-Myers Squibb Company will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial information and will address inquiries from investors and analysts.
- Business Wire
Bristol‑Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
- Zacks
Could the Trade War be Bullish for Stocks?
Tariffs, tweets, negotiations, the Fed cutting rates, full employment, a manufacturing slowdown: how investors can cut through the noise.
- Zacks
AVEO Surges on Favorable Updated OS Results on RCC Drug
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
- Zacks
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
- Zacks
4 Big Drugmakers Boasting Impressive Oncology Pipelines
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
- Kiplinger
7 Cheap Stocks to Buy in a Pricey Market
After a bull market that's now the longest on record, you might think that nothing is cheap anymore. How one precisely defines "cheap" can vary from person to person. But for many, cheap stocks are simply those with solid fundamentals that have either been overlooked by the market or excessively knocked down by bad news.The one game you don't want to play is buying stocks just because they have fallen in price. While some may truly be great bargains, others fall for good reason. That reason can be anything from failing business models and weak management to overwhelming legal issues, changing tastes and obsolete technology.To separate the wheat from the chaff, we've asked a group of investment managers and market experts which stocks are in the "good bargain" category, which means they're down in price but still fundamentally sound and growing.Here are seven of their favorite cheap stocks to buy. Most of the names are familiar, which will provide an additional level of comfort. However, they all share a common thread of being down but far from out. SEE ALSO: 50 Top Stocks That Billionaires Love
- American City Business Journals
Aveo CEO says new data eases concerns about troubled kidney cancer drug
In the two-year study of 350 subjects who had taken two previous cancer treatments, Aveo Oncology's renal cell carcinoma treatment tivozanib was linked to a lower risk of death than the current standard of care.
- Business Wire
Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated a greater than five-fold increase in five-
